The test, a cell-free DNA test, uses a sample of the mother's blood to screen for certain conditions in the developing fetus ...

Genfit has announced encouraging preliminary results from its phase 1b clinical trial evaluating investigational drug GNS561 in combination with a MEK inhibitor (MEKi) in patients with KRAS mutated ...

Highly encouraging early data from the ongoing Phase 1b study evaluating investigational drug GNS561 with a MEK inhibitor (MEKi) in KRAS mutated ...

When Cindy Mrotek and Katie Glenn became caregivers for their parents with cholangiocarcinoma, but they didn’t just find ...

NANJING, China and GAITHERSBURG, Md., Dec. 4, 2025 /PRNewswire/ -- TransThera Sciences Inc. ("TransThera") announced the publication of clinical results from a US-based Phase 2 trial evaluating ...

Cindy and Katie share how caring for parents with cholangiocarcinoma led to friendship, support and advocacy through the Cholangiocarcinoma Foundation. While the FDA approval of Truseltiq for ...

The manufacturer, QED Therapeutics, cited difficulties in recruiting and enrolling participants in the confirmatory study. The Food and Drug Administration (FDA) has made the final decision to ...

Each anatomical subtype of cholangiocarcinoma, intrahepatic (iCCA), perihilar (pCCA) and distal (dCCA), has a distinct epidemiology, biology, and prognosis, thus necessitating different management ...

If you’ve spent any time working in or around Fred Hutch Cancer Center, you might convince yourself that researchers are well on their way to treating or even curing the majority of human cancers.

Coverage from the 2022 annual meeting of the Cholangiocarcinoma Foundation, which met February 23-25 in Salt Lake City, Utah. As recently as 2006, cholangiocarcinoma (or biliary duct cancer) did not ...